Evidence map›Paper›PMID 38840811›Full record

ArticleSociete internationale d'urologie journal : SIUJ2022

2022 WUOF/SIU International Consultation on Urological Diseases: Genetics and Tumor Microenvironment of Renal Cell Carcinoma.

Sari Khaleel, Christopher Ricketts, W Marston Linehan, Mark Ball, Brandon Manley, Samra Turajilic, James Brugarolas, Ari Hakimi

Abstract read
In one paragraph

Article in Societe internationale d'urologie journal : SIUJ, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sari KhaleelUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, United States.ORCID 0000-0002-0886-0860
Christopher RickettsUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, United States.ORCID 0000-0003-4814-7207
W Marston LinehanUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, United States.
Mark BallUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, United States.ORCID 0000-0003-1780-2627
Brandon ManleyDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States.ORCID 0000-0002-7927-1510
Samra TurajilicThe Francis Crick Institute, London, United Kingdom.ORCID 0000-0001-8846-136X
James BrugarolasKidney Cancer Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, United States.ORCID 0000-0002-8575-499X
Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, United States.ORCID 0000-0002-0930-8824

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Renal cell carcinoma is a diverse group of diseases that can be distinguished by distinct histopathologic and genomic features. In this comprehensive review, we highlight recent advancements in our understanding of the genetic and microenvironmental hallmarks of kidney cancer. We begin with clear cell renal cell carcinoma (ccRCC), the most common subtype of this disease. We review the chromosomal and genetic alterations that drive initiation and progression of ccRCC, which has recently been shown to follow multiple highly conserved evolutionary trajectories that in turn impact disease progression and prognosis. We also review the diverse genetic events that define the many recently recognized rare subtypes within non-clear cell RCC. Finally, we discuss our evolving understanding of the ccRCC microenvironment, which has been revolutionized by recent bulk and single-cell transcriptomic analyses, suggesting potential biomarkers for guiding systemic therapy in the management of advanced ccRCC.

Indexed as

clear cell carcinomageneticsnon-clear cell renal cell carcinomaRenal cell carcinomatumor microenvironment

Identifiers

PMID38840811
PMCPMC11151163

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.